Table 2.
List of completed and ongoing clinical trials of NK cell therapy on GBM was obtained from https://www.clinicaltrials.gov (keywords: glioblastoma and NK cells) until November 2022.
| No. | Study name | Identifier | Condition or disase | Treatment | Study phase | Description | Status | Starting date |
|---|---|---|---|---|---|---|---|---|
| I | Intracrani al Injection of NK-92/5.28.z Cells in Patients With Recurrent HER2- posit ive Glioblastoma (CAR2BRATN) |
NCT03383978 | • Glioblastoma | • NK-92/5.28.z | Phase I | Multicenter, Open Label, Phase I Study of I ntracranial I njection of NK-92/5.28.z Cells in Patients With Recurrent HER2- positive Glioblastoma |
Recruiting | December 2017 |
| 2 | NK Cell Therapy for Recurrent Glioblastoma Multifom1 Patients |
NCT05108012 | • Glioblastoma Multiforme • Recurrent Glioblastoma |
• NK cell therapy | Phase I | The Safety Evaluation of Ex Vivo Activated Haploidentical Natural Killer Cells (NK) in Recurrent Glioblastoma Mu ltifonn Patients (Clinical Trial Phase I ) |
Recruiting | August 2021 |
| 3 | Intra-tumoral Inject ion of Natural Killer Cells in High- Grade Gliomas (NK HGG) | NCT04254419 | • High Grade Glioma | • NKcells | Phase I | Phase I Study of Intra- Tumoral Injections of Autologous Ex Vivo Expanded Natural Killer Cells in Children With Recurrent High- Grade Glioma |
Not yet recruiting | July 2022 |
| 4 | Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Glioblastoma | NCT04991870 | • Recurrent Gliosarcom a • Recurrent Supratentorial Glioblastom a • Supratentorial Gliosarcoma |
• Cord Blood-derived Expanded Allogeneic Natural Killer Cells | Phase I | This phase I trial is to find out the best dose.possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 and NR3C1 (cord blood [CBJ- NK-TGF-betaR2-/NR3C1 -) in treating patients with glioblastoma that has come back (recurrent). CB- K- TGF-betaR2- /NR3C1 - cells are genetically changed immune cells that may help to control the disease. |
Not yet recruiting | August 2022 |
All data were collected from studies with only NK cell treatment. Data from withdrawn, terminated, and suspended studies were excluded from the final summary.